NEW YORK |
(Reuters) - Michael Weitz had options. The Californian had undergone chemotherapy, radiotherapy and surgery, but his lung cancer still spread to his bones and the brain.
With time running out, the doctor of the emergency room is entered a phase I study - the first step in human testing of a new drug - of crizotinib. The drug works for about 4 percent of patients with advanced lung cancer with a mutated form of a protein called ALK.
